research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
AZD6244 treatment causes skin aging effects by depleting skin stem cells.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases
OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Minoxidil (Mx) as a prophylaxis of doxorubicin – induced alopecia
Minoxidil not effective in preventing chemotherapy-induced hair loss.
research Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
research Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
JAK inhibitors helped treat hair loss in two people with Down syndrome.
research Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
Tofacitinib helped a woman with total-body hair loss grow her hair back.
research LB1048 Effectiveness of OR-101 in a murine model of atopic dermatitis
OR101 may effectively treat atopic dermatitis and similar skin conditions.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research The Role of Tofacitinib in the Management of Alopecia Totalis
Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
research S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
research BH06: Clinical trial of combination therapy with oral hydroxychloroquine and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia
research The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
JAK inhibitors are effective and safe for treating severe alopecia areata.
research Doxazosin + finasteride in BPH with TPV ??? 25mL
research Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
research A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
research Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia
Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Evaluation of Serum Ferritin, Creatinine and Liver Enzymes in Patients with ß- thalassemia After Administration of Deferasirox
Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
research Characterization of recombinant human liver dehydroepiandrosterone sulfotransferase with minoxidil as the substrate
Human liver enzyme DHEA ST helps process minoxidil.
research Logic-Based Modeling and Drug Repurposing for the Prediction of Novel Therapeutic Targets and Combination Regimens against E2F1-Driven Melanoma Progression
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
research Dermpath & Clinic: Telangiectasia macularis eruptiva perstans
Brodalumab is more effective than ustekinumab in treating psoriasis.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.